Division of Pulmonary and Critical Care Medicine, Univ. of Miami, Miller School of Medicine, FL 33136, USA.
Am J Physiol Lung Cell Mol Physiol. 2011 Feb;300(2):L204-15. doi: 10.1152/ajplung.00292.2010. Epub 2010 Nov 19.
Cigarette smoke represents a major risk factor for the development of chronic obstructive pulmonary disease (COPD), a respiratory condition associated with airflow obstruction, mucus hypersecretion, chronic inflammation, and upregulation of inflammatory mediators such as the monocyte chemotactic protein-1 (MCP-1). MCP-1 through its receptor CCR2 induces chemotaxis and activates (44/42)MAPK, a kinase known to play a key role in mucin regulation in bronchial epithelium. In the present study we used differentiated primary cultures of normal human bronchial epithelial (NHBE) cells to test whether MCP-1 through its receptor CCR2 induces mucin upregulation. We have provided evidence that NHBE cells release MCP-1 to the epithelial surface and express the CCR2B isoform of the receptor mainly at the apical pole. In addition, we found that MCP-1 has a novel function in airway epithelium, increasing the two major airway mucins MUC5AC and MUC5B, an effect mediated, at least in part, by a cascade of events initiated by interaction of its receptor CCR2B with G(q) subunits in caveolae, followed by PLCβ, PKC, and (44/42)MAPK activation. We also have shown that MCP-1 is able to induce its own expression using the same receptor but through a different pathway that involves RhoA GTPase. Furthermore, we found that a single exposure to MCP-1 is enough to induce MCP-1 secretion and sustained mucin upregulation up to 7 days after initial exposure, an effect mediated by CCR2B as confirmed using short hairpin RNA. These results agree with our data in smoker's airway epithelium, where CCR2B is present in MUC5AC- and MUC5B-expressing cells and augmented MCP-1 expression is associated with increased MUC5AC and MUC5B immunolabeling, suggesting that the mechanisms described in primary cell cultures in the present study are operative in vivo. Therefore, therapeutic approaches targeting MCP-1/CCR2B may be useful in preventing not only influx of inflammatory cells to the airways but also mucus hypersecretion and goblet cell hyperplasia.
香烟烟雾代表了慢性阻塞性肺疾病(COPD)发展的主要危险因素,COPD 是一种与气流阻塞、黏液过度分泌、慢性炎症以及炎症介质上调(如单核细胞趋化蛋白-1(MCP-1))相关的呼吸道疾病。MCP-1 通过其受体 CCR2 诱导趋化作用并激活(44/42)MAPK,该激酶已知在支气管上皮细胞中黏液调节中发挥关键作用。在本研究中,我们使用分化的正常人支气管上皮(NHBE)细胞原代培养物来测试 MCP-1 是否通过其受体 CCR2 诱导黏液上调。我们已经提供证据表明 NHBE 细胞向上皮表面释放 MCP-1,并主要在顶端表达受体的 CCR2B 同工型。此外,我们发现 MCP-1 在气道上皮中具有新的功能,增加了两种主要的气道黏液 MUC5AC 和 MUC5B,这种作用至少部分是由其受体 CCR2B 与小窝中的 G(q)亚基相互作用引发的级联事件介导的,随后是 PLCβ、PKC 和(44/42)MAPK 激活。我们还表明,MCP-1 能够通过与相同受体的不同途径诱导自身表达,该途径涉及 RhoA GTPase。此外,我们发现单次暴露于 MCP-1 足以诱导 MCP-1 分泌,并在初始暴露后 7 天内持续诱导黏液上调,这种作用通过 CCR2B 介导,如使用短发夹 RNA 所证实的。这些结果与我们在吸烟者气道上皮中的数据一致,其中 CCR2B 存在于 MUC5AC 和 MUC5B 表达的细胞中,并且增强的 MCP-1 表达与增加的 MUC5AC 和 MUC5B 免疫标记相关,表明本研究中在原代细胞培养物中描述的机制在体内起作用。因此,针对 MCP-1/CCR2B 的治疗方法可能有助于不仅预防炎症细胞流入气道,还预防黏液过度分泌和杯状细胞增生。